{"created":"2023-05-15T16:36:53.728016+00:00","id":10097,"links":{},"metadata":{"_buckets":{"deposit":"19b0c562-3ecf-418d-8983-5692f8ff43c0"},"_deposit":{"created_by":2,"id":"10097","owners":[2],"pid":{"revision_id":0,"type":"depid","value":"10097"},"status":"published"},"_oai":{"id":"oai:nagasaki-u.repo.nii.ac.jp:00010097","sets":["29:30:1713167819629:769"]},"author_link":["40586","40587","40595","40591","40588","40594","40596","40592","40597","40589","40593","40590"],"item_3_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2012-04","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"4","bibliographicPageStart":"1","bibliographicVolumeNumber":"57","bibliographic_titles":[{"bibliographic_title":"Acta Medica Nagasakiensia"}]}]},"item_3_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Background. Geranylgeranylacetone (GGA), which is an isoprenoid compound, has been used orally as an antiulcer drug in\nJapan. GGA induces antiviral gene expression by stimulating the formation of interferon-stimulated gene factor 3 in human\nhepatoma cells. This study verified the anti-hepatitis C virus (HCV) activity of GGA in chronic hepatitis C-infected patients.\nMethods. The present prospective study included 20 consecutive anti-HCV antibody-positive, HCV-genotype 1b, and chronic\ngastritis patients who visited Nagasaki University Hospital between January 1999 and December 1999. GGA (150 mg per day,\nwhich is the dose generally used for chronic gastritis) was taken orally for four weeks. We evaluated HCV-RNA titers and other\nclinical parameters at pretreatment, posttreatment, and at the endpoint of the study. Pretreatment was the beginning point of\nGGA treatment. Posttreatment was the termination point of GGA treatment. The endpoint was the point four weeks after the\nposttreatment point.\nResults. All patients completed four weeks of GGA treatment and four weeks of observation. HCV-RNA titers at postpoint\nwere not significantly diminished compared to those at pretreatment. However, HCV-RNA titers were significantly diminished\nat endtreatment compared to pretreatment. Unfortunately, we did not observe a case with no titer of HCV-RNA. Alanine\naminotransferase values and other parameters were not affected by GGA treatment.\nConclusion. GGA has anti-HCV activities in chronic hepatitis C-infected patients. In the future, it will be necessary to examine\nthe clinical effectiveness of the combination of treatment with both GGA and interferon in HCV patients.","subitem_description_type":"Abstract"}]},"item_3_description_64":{"attribute_name":"引用","attribute_value_mlt":[{"subitem_description":"Acta Medica Nagasakiensia, 57(1), pp.1-4; 2012","subitem_description_type":"Other"}]},"item_3_publisher_33":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Nagasaki University School of Medicine"}]},"item_3_source_id_10":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AA00508430","subitem_source_identifier_type":"NCID"}]},"item_3_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"00016055","subitem_source_identifier_type":"ISSN"}]},"item_3_text_62":{"attribute_name":"sortkey","attribute_value_mlt":[{"subitem_text_value":"01"}]},"item_3_text_63":{"attribute_name":"出版者別言語","attribute_value_mlt":[{"subitem_text_value":"長崎大学医学部"}]},"item_3_version_type_16":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Yamaguchi, Tohei"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Ichikawa, Tatsuki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Takeshita, Shigeyuki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Taura, Naota"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Miyaaki, Hisamitsu"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Muraoka, Toru"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Shibata, Hidetaka"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Honda, Takuya"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Hamasaki, Keisuke"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kato, Yuji"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Takeshima, Fuminao"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Nakao, Kazuhiko"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-12-22"}],"displaytype":"detail","filename":"ActMed57_1.pdf","filesize":[{"value":"138.9 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"ActMed57_1.pdf","url":"https://nagasaki-u.repo.nii.ac.jp/record/10097/files/ActMed57_1.pdf"},"version_id":"3f3343f2-63ec-4217-a2d6-13c045dce2eb"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Hepatitis C virus","subitem_subject_scheme":"Other"},{"subitem_subject":"geranylgeranylacetone","subitem_subject_scheme":"Other"},{"subitem_subject":"chronic hepatitis C","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Anti-hepatitis C virus activity of geranylgeranylacetone treatment in hepatitis C-infected patients","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Anti-hepatitis C virus activity of geranylgeranylacetone treatment in hepatitis C-infected patients"}]},"item_type_id":"3","owner":"2","path":["769"],"pubdate":{"attribute_name":"公開日","attribute_value":"2012-05-16"},"publish_date":"2012-05-16","publish_status":"0","recid":"10097","relation_version_is_last":true,"title":["Anti-hepatitis C virus activity of geranylgeranylacetone treatment in hepatitis C-infected patients"],"weko_creator_id":"2","weko_shared_id":2},"updated":"2024-04-16T05:30:41.121512+00:00"}